Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (42266)	1/5/1999 12:59:00 PM
From: Peter Singleton	Read Replies (1) \| Respond to of 132070

CB, You're in luck (sort of) since there are some folks posting on SI who are among the sharpest biotech investment minds out there. That said, valuing biotechs is probably the hardest thing I've tried to do in investing. Michael is right that it all boils down to CAPM, but the input variables and the timeframes don't lend themselves well to objectification. Another thing to consider with respect to biotechs is they're likely to get slammed in an overall market decline ... despite the fact that many of them sell for attractive values, even after the recent months's strong run by these stocks. But, if you're willing to tread carefully, and spend a bunch of time educating yourself, there's incredible value being created in the industry, and SI is a great place to follow the biotechs. top notch folks include: Larry Liebman Member 2032021 Miljenko Zuanic Member 3265052 Pseudo Biologist Member 1399203 Rick Harmon Member 1178063 Peter Suzman Member 863789 Vector1 Member 3302975 There are other folks who are topnotch, too, e.g., James Silverman, Henry Niman (Henry's hopelessly infatuated with the company he founded, LGND, but he's incredibly sharp when he assesses other companies ... ) A good thread to follow is: VD's [Vector1 and Rocketman Dave's] Model Portfolio & Discussion Thread Subject 14492 BTW, for my money, the two best folks to listen to for their investment probity are Peter Suzman and Vector1. Both are very, very sharp guys, with strong business backgrounds, who've done their homework in learning enough of the science to not get snowed when they evaluate companies. But if you're starting a team, the best all-around player is Rick Harmon. His background is in the science (immunology, I believe), he's worked in the industry since it's early stages, and he's a tireless proponent on SI and other places for honest, careful evaluation of both the science and the business prospects of these companies. Good luck with your biotech investing! Peter